Pediatric Hematology/Oncology Trials

UnityPoint Clinic Urgent Care - Altoona

Closed Patients
Waiting Now

UnityPoint Clinic Urgent Care - Ingersoll

Closed Patients
Waiting Now

Urgent Care - Ankeny

Closed Patients
Waiting Now

Urgent Care - Lakeview

Closed Patients
Waiting Now

Urgent Care - Merle Hay

Closed Patients
Waiting Now

Urgent Care - Southglen

Closed Patients
Waiting Now

Urgent Care - Urbandale

Closed Patients
Waiting Now
Blank Children's Hospital

Pediatric Hematology/Oncology Clinical Trials

Central Nervous System

ACNS0831: Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma 

ACNS1422: A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients


AALL1131: A Phase III Randomized Trial for Newly Diagnosed High Risk B-ALL Including a Stratum Evaluating Dasatinib in Patients with Ph-like TKI Sensitive Mutations

AALL1521: A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway–Mutant ALL

AALL15P1: A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine to Chemotherapy in Infants with ALL and KMT2A (MLL) Gene Rearrangement

AALL1621: A Phase 2 Study of Inotuzumab Ozogamicin in Children and Young Adults with Relapsed or Refractory CD22+ B-ALL

AALL1631: International Phase 3 Trial in Philadelphia. Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones

AAML1531: Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome

Leukemia / Lymphoma

AALL1231: A Phase III Randomized Trial Investigating Bortezomib on a Modified Augmented BFM Backbone in Newly Diagnosed T-ALL and T-LLy


AHOD1331: A Randomized Phase III Study of Brentuximab Vedotin for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents

ANHL12P1: A Randomized Phase II study of Brentuximab Vedotin and Crizotinib in Patients with Newly Diagnosed Anaplastic Large Cell Lymphoma

Germ Cell

AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors


ANBL1232: Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma

ANBL1531: A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma. 


AEWS1221: Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma

ARST1321: Pazopanib Neoadjuvant Trial In Non-Rhabdomyosarcoma Soft Tissue Sarcomas: A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib

ARST1431: A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide Alternating with Vincristine and Irinotecan Versus VAC/VI Plus Temsirolimus in Patients with Intermediate Risk Rhabdomyosarcoma

Refractory Tumors

ADVL1322: A Phase II Trial of Pazopanib in Children with Refractory Solid Tumors

ADVL1622: Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors

Match Trial

APEC1621 SC: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

APEC1621 A: Phase 2 subprotocol of LOXO-101 in patients with tumors harboring actionable NTRK fusions

APEC1621 B: Phase 2 subprotocol of JNJ-42756493 (Erdafitinib) in patients with tumors harboring FGFR1/2/3/4 alterations

APEC1621 C: Phase 2 subprotocol of tazemetostat for patients with tumors harboring alterations in EZH2 or members of the SWI/SNF complex

APEC1621 D: Phase 2 subprotocol of LY3023414 in Solid Tumors

APEC1621 E: Phase 2 subprotocol of Selumetinib in patients with Tumors harboring activating MAPK pathway mutations.

APEC1621 F: Phase 2 subprotocol of Ensartinib in patients with tumors harboring ALK or ROS1 genomic alterations

APEC1621 G: Phase 2 subprotocol of Vemurafenib in patients with tumors harboring actionable BRAF V600 mutations

APEC1621 H: Phase 2 subprotocol of olaparib in patients with tumors harboring defects in DNA damage repair genes

APEC1621 I: Phase 2 subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes

APEC1621 J: Phase 2 Subprotocol of BVD-523FB (ulixertinib) in Patients with Tumors Harboring Activating MAPK Pathway Mutations

Registry, Biology & Banking

APEC14B1: Project:EveryChild A Registry, Eligibility Screening, Biology and Outcome Study

ANBL00B1: Neuroblastoma Classification Biology Studies

AREN03B2: Renal Tumors Classification, Biology, and Banking Study

Cancer Control

ACCL10P1: Computerized Cognitive Training for Pediatric Brain Tumor Patients: A Pilot Study

ACCL1333: A Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoma (T or B cell) Treated with Pegylated Asparaginase

Survivorship/Late Effects

ALTE05N1: Umbrella Long-term Follow-up Protocol

ALTE07C1: Neuropsychological, Social, Emotional and Behavioral Outcomes in Children with Cancer

ALTE15N2: LEAHRN (Late Effects After High-Risk Neuroblastoma) Study

ALTE1621: Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial

Cancer Care Delivery Research

ACCL15N1CD: Use of Evidence-Based Supportive Care Clinical Practice Guidelines in Pediatric Oncology

ACCL16N1CD: Documentation and Delivery of Guideline-Consistent Treatment in AYA ALL

Sponsored Trials

1160.106: Open-label, randomized, parallel-group, active-controlled, multi-centre, non-inferiority study of dabigatran etexilate versus standard of care for venous thromboembolism treatment in children from birth to less than 18 years of age: The DIVERSITY study

1160.108: Open label, single arm safety prospective cohort study of dabigatran etexilate for secondary prevention of venous thromboembolism in children from 0 to less than 18 years

1321.7: Reversal Dabigatran Anticoagulant Effect With Idarucizumab

CV185-118: Single Dose Apixaban for Thrombosis Prevention

IM2008-006: Severe Chronic Neutropenia International Registry